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Abstract
Background: Increasing numbers of ovarian cancer patients are living longer and requiring regular follow-up to
detect disease recurrence. New models of follow-up care are needed to meet the growing number and needs of
this patient group. The potential for patient-reported outcome measures (PROMs) to capture key symptoms and
online technology to facilitate long-term follow-up has been suggested.
Objectives: Prior to a pilot study exploring the potential for electronic patient-reported symptom monitoring, the
content of an online intervention was developed via Delphi methodology.
Design and setting: A Delphi process was conducted aiming to obtain consensus amongst the clinicians and
patients from 4 hospitals on the key aspects to monitor during follow-up after ovarian cancer treatment, and how
to monitor them in an online intervention. A two round Delphi was conducted. Consensus was defined as at least
70% agreement.
Results: Out of 43 participants, 30 (18 patients, 12 healthcare professionals) completed round 1 and 19 (11 patients,
8 healthcare professionals) completed round 2. Consensus was reached on the key symptoms to monitor, and the
importance of monitoring both duration and frequency of symptoms. Opportunity for review of psychological
wellbeing and holistic needs were considered important by both groups. The frequency of online questionnaire
completion, timeframe for patients to reflect on (e.g. during the past X weeks), and the choice of PROMs items to
monitor symptoms did not reach the consensus threshold.
Conclusion: It is crucial that any intervention and the selection of PROMs is fully described to ensure transparency
about the development and decisions taken. In this work, a set of key symptoms and areas to monitor were agreed,
which has informed the design of an online intervention and a subsequent pilot study is now underway. The
proposed model of remote follow-up using electronic PROMs could be adapted and explored in other cancer sites.
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Plain English summary
What is the key problem/issue/question this manu-
script addresses?
With growing numbers of patients living longer
following cancer treatment, new models of follow-up
care are needed. Using technology, symptoms can be
monitored remotely as part of long term follow-up, but
this requires careful planning to ensure it meets patient
needs.
Why is this study needed?
It is important to explore the views of patients and
healthcare professionals so they can contribute to the
design of any new follow-up process.
What is the main point of your study?
Before piloting a web-based system, we conducted a
survey amongst patients and healthcare professionals to
gather their views about the symptom-related questions
we should ask, and how often patients should be answer-
ing these in order to manage symptoms/side effects and
detect recurrence.
Provide a brief overview of your results and what
they mean.
Patients and healthcare professionals agreed on the
key symptoms to monitor, and the importance of having
an opportunity to report and request support for any
holistic needs following treatment. Differences of
opinion were highlighted in how often symptoms should
be reported. This work has informed a web-based symp-
tom reporting system which is being piloted within a
community follow-up pathway.
Introduction
Ovarian cancer survival is improving, leading to an
increase in patients on routine follow-up and growing
pressure on clinics as incidence rates are expected to
rise further [1]. Ovarian cancer follow-up is not
protocol-driven and evidence-based best practice is
yet to be established [2]. Current practice involves
monitoring symptoms and serum biomarkers (CA125)
through routine appointments to detect recurrence,
which is likely to occur within 5 years [3]. Evidence
is scarce on the value of routine follow-up for sur-
vival or quality of life [4]. Nama et al. [5] suggested
that follow-up could utilise patient-reported outcome
measures (PROMs) as symptoms are often present at
the point of relapse. Research has also indicated that
patients delay help-seeking for symptoms until their
next appointment [6], and some gynaecological pa-
tients have high anxiety before/during appointments
[7]. More sustainable models of follow-up and long-
term symptom tracking are clearly needed to ensure
care provision is commensurate with patient need, ra-
ther than a one-size-fits-all service which may detract
resources from those who need them most [8].
In recent years pilot studies have explored nurse-led
telephone methods [9–12]. Most have been small quali-
tative studies, but they illustrate positive experiences
amongst early endometrial or stage I-IV ovarian cancer
patients. Cox [10] notes the convenience of telephone
follow-up in facilitating psychosocial support and the
reassurance of continued blood tests.
Recent proliferation of modern technology means the
internet offers another follow-up method [13]. Some
patients prefer face-to-face appointments, but a recent
UK-based randomised controlled trial illustrates the
feasibility and patient value of online symptom self-
reporting when clinicians are engaged [14]. Furthermore,
web-mediated follow-up (supplementary, weekly) vs.
routine follow-up has demonstrated increased survival/
earlier relapse detection [15].
To explore the feasibility of an electronic PROMs
(ePROMs) follow-up pathway, the ‘electronic Patient
self-Reported outcomes to Improve cancer Management
and patient Experiences’ (ePRIME) study proposed an
online intervention for ovarian patients following treat-
ment. The intervention included an ePROMs symptom
questionnaire and a blood test to monitor CA125
(performed at GP, local hospital or cancer centre). The
clinical team interpret these results, instead of the pa-
tient attending hospital-based appointments. Prior to
piloting this pathway, decisions about the intervention
content and logistics required consultation, which is an
important step of any intervention development [16].
This paper describes the process undertaken to reach
agreement from healthcare professionals (HCPs) and
patients on the core symptoms for monitoring relapse
and life after treatment, the most appropriate symptom
measure/items, and the frequency of completion to
inform the ePROM intervention.
Methods
A Delphi consultation methodology was chosen as it
offers an iterative consensus-based approach to reach
agreement [17]; group responses are fed back to partici-
pants allowing them to re-assess their views within
multiple rounds. A ‘modified’ Delphi survey [18] was
undertaken which allows the initial round to be in-
formed from group discussions/interviews or a literature
review, and is less prescriptive on the number of rounds
required. The survey was conducted in two iterative
rounds over a 10 month period (Round 1 August 2016–
February 2017, Round 2 February–April 2017, but one
patient completed in June 2017).
Participants
All doctors and clinical nurse specialists (CNS) working
in the gynae medical oncology teams at the four partici-
pating hospitals were invited to complete the online
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survey (https://www.onlinesurveys.ac.uk/) via an email,
including a unique username/password for access. Paper
copies were provided on request.
Patients who were between 6 and 36 months post-
treatment and attending routine ovarian cancer
follow-up were consecutively invited as they could
offer opinions on the proposed online intervention
having experienced the follow-up process. Purposive
sampling aimed to get a mixture of patient ages and
time/experience on follow-up. Patients were
approached by their clinical team, and if willing were
provided with a study information sheet. Following
verbal agreement patients were given a paper survey
and a username/password if they preferred to
complete the online version.
All participants were reminded that the survey was
anonymous, and the survey return was taken as formal
consent. One email/telephone reminder was undertaken.
The demographic details collected included patient
age, time post-treatment, and whether this was their first
diagnosis. HCPs age, gender, role, and years worked in
speciality were collected.
Procedure and Delphi survey content
Ethical approval was obtained from NHS Leeds West
Research Ethics Committee (ref: 16/YH/0239).
Firstly, the key symptoms to monitor during ovarian
cancer follow-up were explored through informal discus-
sions with HCPs at each hospital. A literature review
was conducted to identify and select six potential
PROMs for this clinical group (see Additional file 1:
Appendix 1 for details of the review and the measures).
Figure 1 outlines the survey topics and an abridged
version of each round is presented in Additional file 1:
Appendix 2.
Round 1
Relevant symptom items from each of the six PROMs
(Additional file 1: Appendix 1, Table A1) were selected
and grouped, rather than presenting the full measure
(see Additional file 1: Appendix 2 for an example). Then
participants rated how well the overall set of items cap-
tured the key symptoms to monitor on a 7-point Likert
scale (1 = not at all, 7 = very much). The survey also
explored the frequency of completion in a follow-up
setting, the timeframe for patients to reflect upon (e.g.
during the past X weeks), whether symptom duration/
frequency/change and holistic needs should be captured.
Round 2
The results from round 1 (aggregated percentages from
HCPs, patients, overall) were presented, and further
questions asked where opinion was diverse or new
aspects had emerged since round 1.
Statistical analysis
There is no universal agreement in Delphi methodology
on the percentage that constitutes ‘consensus’, with
recommendations ranging from 51% to 80%, but
Humphrey-Murto et al. (2017) suggested 70% is a typical
cut-off [19] and therefore this was defined a priori as the
proposed target level. A lack of consensus was defined
as percentages below 70% in round 2.
The proportion of each response was also explored
across the participant groups (patients, HCPs, overall).
For items on a Likert scale (e.g. round 1-PROMs rating
1–7), mean scores were calculated for each measure for
each group/overall, and the highest scoring PROMs were
presented in round 2.




Forty-three participants (28 patients/15 HCPs) were
approached, and 30 responded (69.8% response rate), in-
cluding 18/28 patients (64.3%) and 12/15 HCPs (80%).
Table 1 illustrates the demographic characteristics in
both rounds. Half the patients (n = 9) were 6–12months
post-treatment, whilst others were 1–3 years post-
treatment, and for most patients it was their first diagno-
sis (n = 14). The HCPs included at least one consultant
and CNS from each hospital, but more from the largest
hospital (site 1).
The key symptoms agreed were: abdominal pain/dis-
comfort, abdominal swelling/bloating, nausea, vomiting,
appetite loss, change in bowel habit, urinary symptoms,
shortness of breath, fatigue, swollen legs and unexpected
weight change. Table 2 summarises the percentage
agreement for the questions in each round.
Overall 93.3% felt it was important to monitor the
duration and change in symptoms, and 86.7% agreed
that symptom frequency should be explored. Eighty
percent felt ongoing chemotherapy toxicity and psycho-
logical wellbeing were important.
Consensus was not achieved for how frequently
patients should complete the online questionnaire, the
timeframe/period that patients reflected upon (… past X
weeks), and the specific holistic needs question (e.g.
travel insurance, emotional). Similarly, the choice of
which PROMs to use did not reach consensus, but two
options (MDASI-OC; FACT-O) were removed as these
were endorsed the least. HCPs also scored the PRO-
CTCAE low but it was retained into round 2 due to
patient endorsement.
Round 2
15/18 patients wished to be contacted for round 2, and
11/15 completed (73.3%). All HCPs were re-contacted
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regardless if they had completed round 1. One nurse
was no longer working in the speciality, but 8/14 HCPs
completed (57.1%), including 5 consultants and 3 CNS
(5/8 were from site 1, with one representative from the
other 3 sites, see Table 1). Overall 19/29 responded
(65.5%).
Three new areas were consulted (Table 2), namely: the
provision of self-management advice (62.5% HCPs yes,
but 45.5% patients unsure), asking about medication use
(84.2% overall), and weight changes (89.5% overall).
The frequency of completion fell short of reaching
agreement with 68.4% endorsing 3-monthly reports.
However, the acceptability of including a checklist of
holistic needs (e.g. emotional, financial, sexual, work/em-
ployment, family issues) was agreed by 100% HCPs and
81.8% patients.
Sufficient consensus was not reached on the timeframe
(… past X weeks) or the preferred PROMs to use. Given
the time constraints a third round could not be under-
taken. Discussions were held within the project steering
committee, and as around half (47.4% overall) chose ‘ …
past 2 weeks’ this was selected. PROMs opinions varied
widely for three measures across the participant groups
(PRAE 42.1% - 5 patients/3 HCPs; MOST 26.3% - 1 pa-
tient/4 HCPs; PRO-CTCAE 21.1% - 4 patients) (Table
2). Further consultation selected the PRAE as this
measure was endorsed most overall, particularly by
patients who were prioritised as the intended online
system users.
Figure 2 visually presents the symptom monitoring
intervention.
Discussion
This work achieved its aim of exploring the key
symptoms to monitor during ovarian cancer follow-
up, and gathering HCP/patient views of the fre-
quency/proposed content of an online follow-up
intervention. The value of remote online methods to
facilitate follow-up has become increasingly relevant
during/following the COVID-19 pandemic where the
reduction of face-to-face hospital-based appointments
was essential. This has led to calls for rapid introduc-
tion of electronic PROMs in cancer clinical practice
Fig. 1 Schematic showing questions areas on the Delphi panel in each round
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[20] and the continued importance of providing sup-
port for cancer survivors during/following the pan-
demic [21].
For most areas, 70% consensus was achieved within
two rounds, but some major differences were observed
within and between groups. We hope this report
provides transparency of the process [16] to enable
others to learn from our experiences.
Most HCPs felt 3-monthly was an appropriate
frequency (in line with clinical practice), but patients
were divided between monthly and 3-monthly reports.
For the ePRIME pilot 3-monthly was chosen but the
system is open-access should patients wish to complete
earlier. This work highlights the importance and value of
consulting both patient and HCPs equally when develop-
ing interventions [22, 23].
Furthermore, rather than a purely remote system
whereby patients report online without clinical con-
tact, free-text comments and discussions with both
groups led to the decision that a telephone-based
appointment would allow a CNS to formally review
online completions and blood results. Therefore, this
format is being evaluated in the ongoing pilot.
Patients and HCPs placed great value on report-
ing/reviewing holistic needs, adding to the evidence
that holistic needs assessment is integral to deliver-
ing person-centred care [24]. Within the ePRIME
system we specifically ask about non-medical holistic
needs, and we would urge others to continue priori-
tising this important area in research and clinical
practice, especially if follow-up care is being deliv-
ered remotely [23].
The overall survey response rates in both rounds
were ~ 65%, and non-response/attrition reasons were
not collected. Selection bias is possible as non-
responders may have contrasting views of the pro-
posed intervention. Furthermore, those who dropped
out may be different, for example less older patients
(66+ years) completed round 2. However individuals
were consecutively approached, there was a variety of
demographics and hospital sites represented across
both rounds.
Consensus was not reached on the choice of which
PROMs to use, with views divided across patients and
HCPs. However, as discussed the level of percentage
agreement is disputed in the literature, and the stabil-
ity of responses through rounds may be more valu-
able [17]. To our knowledge there is no official
guidance for how to proceed in such circumstances.
In hindsight a third round or a formal consensus
meeting inviting all participants may have been bene-
ficial [22], but with limited time/resources this was
resolved through discussion within the project steer-
ing committee [25]. It may be that Delphi method-
ology is not the most appropriate method of choosing
between similar validated measures.
Conclusions
It is imperative that intervention development and the
selection of PROMs for trials/research is explicitly
described to ensure transparency about the decision-
making and confirm the appropriateness and content
validity of the intervention [16]. The views of patients
and HCPs have informed the development of the
ePRIME follow-up intervention which is being piloted
in two hospitals in the North of England. If success-
ful, the model of remote follow-up pathway and the
ePROM system could be adapted to other cancer
sites.






Age 26–45 5 4
46–55 7 4
Gender Male 3 2
Female 9 6
Professional role Consultant 7 5
CNS 5 3
Time working in ovarian cancer 1–5 years 2 2
6–10 years 6 4
10+ years 4 2
Hospital site Site 1 5 5
Site 2 2 1
Site 3 2 1










How long since last treatment? 6–12months 9 7
1–3 years 9 4
First diagnosis or relapse? First 14 7
Relapse 4 4
Hospital site Site 1 7 4
Site 2 4 3
Site 3 2 0
Site 4 5 4
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Table 2 Results from each round, percentage of agreement for each area and the consequent decisions made
Round 1 N = 30 (12 HCPs, 18 patients)
Areas where consensus reached: % Areas where consensus was not reached: Round 1 findings (overall %, unless otherwise stated)
and any decisions made in italics















(1 = not at all, 7 = very much)
EORTC – HCPs mean 5.75; patient mean 6.12
FACT-O – HCPs mean 5.25; patient mean 5.82
MDASI-OC – HCPs mean 4.58; patient mean 5.59
MOST – HCPs mean 6.00; patient mean 6.24
PRAE – HCPs mean 6.08; patient mean 6.18
PRO-CTCAE – HCPs mean 5.08; patient mean 6.00
MDASI-OC and FACT-O not rated highly so discarded in Round
1; PRO-CTCAE kept due to patient score.









(Options: 4 monthly, 3 monthly, 2 monthly,
monthly, 6 weekly, other)
4 monthly - 0
3 monthly – 36.7% (11/30)
2 monthly – 26.7% (8/30)
Monthly – 20% (6/30)
6 weekly – 13.3% (4/30)
Other – 3.3% 1/30
4 monthly, 6 weekly, ‘other’ discarded in Round 1.
Ask if symptom has got better /








(Options: Last day, last week, last 2 weeks,
last month, since last reported)
Last week – 23.3% (7/30)
Last 2 weeks – 23.3% (7/30)
Last month – 23.3% (7/30)
Since last reported – 23.3% (7/30)
Last day – 6.7% (2/30)
Last day option discarded in Round 1.














List of non-physical holistic needs –
select which items should be presented to
patients to indicate if they are concerned
(e.g. travel insurance, sexual, emotional)
50% (15/30) felt should include all areas
Highest individual items were:
Emotional 40% (12/30),
Psychological 33.3% (10/30)
2 patients said ‘none of areas’
Weight change question Highest scoring option “Have you been concerned about




Other options discarded in Round 1.
Round 2 N = 19 (8 HCPs, 11 patients)








• 3 monthly 68.4%
(13/19; 6/11
patients, 7/8 HCPs)
• 2 monthly 15.8%
(3/19; 2/11
patients, 1 HCPs)
• monthly 15.8% (3/
19) – all patients
Did not quite meet 70% consensus overall, although 87.5% HCPs agreed.
Final decision to complete 3 monthly - with anytime access for patients allowing them to report sooner/
more frequently if needed





• 10.5% (2/19; 1
patient, 1 HCPs)
• 26.3% (5/19; 1
patient, 4 HCPs)
• 42.1% (8/19; 5
patient, 3 HCPs)
• 21.1% (4/19; all
patients)
Did not reach 70% consensus.
Patients chose PRAE most often 5/11 (45.5%) followed by PRO-CTCAE (4/11), HCPs chose MOST 4/8 (50%),
followed by PRAE.
PRAE items chosen as preferred by most overall.
Timeframe/period to reflect on
when answering symptom
questions:
• Last week 15.8%
(3/19; all patients)
• 2 weeks 47.4% (9/
19; 5 patient, 4
HCPs)
• Last month 21.1%
(4/19; 1 patient, 3
HCPs)
• Since last reported
15.8% (3/19; 2
patient, 1 HCPs)
Did not reach 70% consensus.
Both patients and HCPs chose ‘last 2 weeks’ most often.
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Table 2 Results from each round, percentage of agreement for each area and the consequent decisions made (Continued)
List of non-physical holistic needs
Part 1: “Would a page like this be
acceptable to you?” and
Part 2: should patients be able to
tick which issues they’d like specific
advice/contact with their clinical/CNS
about?












Include holistic needs and ask patients if they need advice/ contact with their clinical/CNS team in
relation to these
Further new areas consulted on: Final decisions made:
Provision of self-management
advice






2 patients chose ‘other’ indicating they’d
want option to speak to nurse over the
phone.
Split between ‘yes’ amongst HCPs, and no/unsure amongst
patients.
Free text comments suggested that at least contact details
should be provided.
Final decision to include self-management advice for











Ask about medication use in






Would this question ‘Have you
been concerned about changes







“Unexpected” weight changes were always the focus of this
item, and emphasised again in Round 2 free-text comments
- item changed to “Have you been concerned about un-
expected changes in your weight?”
1
Paent on gynae cancer 
follow up at home
Receives text message 
and/or email reminder 
















Have you had pain or discomfort in the abdomen 
(belly area)?     0 – No 
1 – I had mild pain or discomfort
2 – I had moderate pain or discomfort and I was not 
able to do some of the things I normally do
3 – I had severe pain or discomfort and I was not able 





















IF PATIENT REPORTS A 
SYMPTOM THEY ARE ASKED:
- How many weeks ago did you first 
noce [symptom]?
Response opon: 0-12 weeks
- How oen do you experience 
[symptom]?  Response:  Rarely, 
Occasionally, Frequently, Almost 
constantly
- Free text box – Please feel free to add 
more detail about your [symptom] 
- Very severe/Severe symptoms
- Moderate symptoms 
lasng > 2 weeks 
- Mild abdominal 
symptoms lasng > 3 weeks
Advice to paent & email alert 
sent to clinical team if:
Are you taking 
medicaon for any of 
your symptoms?
HOLISTIC NEEDS
Have you had parcular 
concerns with any of the following?
 Emoonal (i.e. Worrying and 
anxiety)










Would you like 
support with 
these issues?
Check for details of 
blood test to monitor 
CA125 tumour marker
5
When did you last 
have your blood 
tested?
Where did you last 
have your blood 
tested?
Do you need to speak to 
your Gynaecology Clinical 
Nurse Specialist before 
your next scheduled 
review date? 
Appointment request email 
alert sent to clinical team
IF YES:
Self-management advice given 
for mild symptoms including 








Fig. 2 Overview of the final symptom monitoring intervention
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